Minerva Neurosciences (NERV) Other Non-Current Assets (2013 - 2021)
Minerva Neurosciences' (NERV) quarterly Other Non-Current Assets came in at $14808.0 in Q2 2021, little changed YoY from $14808.0 in Q2 2020, and little changed on a QoQ basis from $14808.0 in Q1 2021.
Analysis
Minerva Neurosciences (NERV) Other Non-Current Assets (2013 - 2021) Analysis & Trends
Minerva Neurosciences (NERV) has 7 years of Other Non-Current Assets data on file, last reported at $14808.0 in Q2 2021.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $14808.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $14808.0 (changed 0.0% YoY) and the FY2020 annual result came in at $14808.0, changed 0.0% from the prior year.
- Other Non-Current Assets steadied at $14808.0 in Q2 2021, from $14808.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $14808.0 in Q4 2017 to a low of $14808.0 in Q4 2017.
- A 5-year average of $14808.0 and a median of $14808.0 in 2017 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 0.0% in 2018, down 0.0% in 2018.
- Tracing NERV's Other Non-Current Assets over 5 years: stood at $14808.0 in 2017, then changed by 0.0% to $14808.0 in 2018, then changed by 0.0% to $14808.0 in 2019, then changed by 0.0% to $14808.0 in 2020, then changed by 0.0% to $14808.0 in 2021.
- The last three Other Non-Current Assets figures came in at $14808.0 (Q2 2021), $14808.0 (Q1 2021), and $14808.0 (Q4 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 14,808.00 |
| Mar 31, 2021 | 14,808.00 |
| Dec 31, 2020 | 14,808.00 |
| Sep 30, 2020 | 14,808.00 |
| Jun 30, 2020 | 14,808.00 |
| Mar 31, 2020 | 14,808.00 |
| Dec 31, 2019 | 14,808.00 |
| Sep 30, 2019 | 14,808.00 |
| Jun 30, 2019 | 14,808.00 |
| Mar 31, 2019 | 14,808.00 |
| Dec 31, 2018 | 14,808.00 |
| Sep 30, 2018 | 14,808.00 |
| Jun 30, 2018 | 14,808.00 |
| Mar 31, 2018 | 14,808.00 |
| Dec 31, 2017 | 14,808.00 |
| Jun 30, 2014 | 3.11 Mn |
| Dec 31, 2013 | 433,998.00 |